Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liafensine in Treatment-Resistant Depression
NCT05113771Phase 2Completed
- Sponsor
- Denovo Biopharma
- Start
- Jun 2022
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of liafensine in major depressive disorder (MDD), sponsored by Denovo Biopharma. Started Jun 2022; status: completed.
02
Drugs
liafensine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05113771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05113771.